S2632 |
BMS-378806
|
BMS-378806 (BMS 806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus. |
-
Commun Biol, 2023, 6(1):535
-
J Virol, 2021, 95(24):e0052921
-
J Virol, 2020, 10.1128/JVI.00148-20
|
|
S8960 |
CD38 inhibitor 1 (compound 78c)
|
CD38 inhibitor 1 (compound 78c, CD38-IN-78c, MDK-7553) is a potent inhibitor of CD38 with IC50 of 7.3 nM and 1.9 nM for human CD38 and mouse CD38, respetively. |
-
Cell Rep Med, 2024, 5(2):101400
-
Cell Rep Med, 2023, S2666-3791(23)00310-5
-
Cell Rep Med, 2023, 4(9):101157
|
|
A2837 |
Anti-CD83
|
Anti-CD83 is a humanized monoclonal antibody against CD83 with the potential to treat auto-immune diseases. MW: 144.8 KD. |
|
|
S5525 |
SodiuM Metatungstate
|
Sodium metatungstate (SMT) solution is an inorganic heavy liquid which is widely used in density fractionation. Sodium metatungstate (Sodium polyoxotungstates) is a potent and selective inhibitor of ecto-nucleoside triphosphate diphosphohydrolase (NTPDases, CD39) with Ki of 0.140 μM, 0.910 μM and 0.563 μM for NTPDase1, NTPDase2 and NTPDase3, respectively. |
-
Cancer Immunol Immunother, 2024, 73(6):108
-
Immunology, 2022, 10.1111/imm.13493
-
Cancer Cell, 2021, 39(7):973-988.e9
|
|
S6239 |
PMX-53
|
PMX-53 is a potent CD88 (C5aR) antagonist and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2). |
-
Thromb J, 2022, 20(1):24
|
|
A2027 |
Daratumumab (anti-CD38)
|
Daratumumab (anti-CD38) is a recombinant monoclonal antibody to CD38. Daratumumab is an investigational anti-cancer drug which is indicated for the treatment of adult patients with multiple myeloma. MW =145.4 kDa. |
-
Brain Behav Immun Health, 2024, 42:100865
-
J Exp Med, 2022, 219(9)e20220214
|
|
S0141 |
NQ301
|
NQ301 (Compound 211), an antiplatelet and antithrombotic agent, is a selective CD45 inhibitor with IC50 of 200 nM. NQ301 inhibits thromboxane A2 receptor (TXA2) and synthase activity in rabbit platelets. |
-
J Extracell Vesicles, 2021, 10(5):e12078
|
|
S9867 |
LY-3475070
|
LY-3475070 is a potent, selective and orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73, 5'-ecto-nucleotidase, 5'-NT, ecto-5'-nucleotidase). |
-
Theranostics, 2024, 14(3):1224-1240
-
Immunology, 2022, 10.1111/imm.13493
|
|
A2029 |
Relatlimab (anti-LAG-3)
|
Relatlimab (BMS-986016, RELA) is a human LAG-3 specific monoclonal antibody that binds to LAG-3 on T cells, restoring effector function of exhausted T cells. |
-
Mol Ther Nucleic Acids, 2024, 35(2):102225
-
J Clin Invest, 2023, 133(9)e164528
|
|
S0474 |
Avacopan
|
Avacopan is an orally administered and selective C5a receptor (C5aR) antagonist. |
-
Nat Commun, 2024, 15(1):6519
-
Cell Death Dis, 2022, 13(5):500
|
|
A2372 |
Apamistamab (Anti-PTPRC / CD45)
|
Apamistamab (Anti-PTPRC / CD45) is an IgG1 anti-CD45 monoclonal antibody (MoAb). Note: This antibody is not labeled with the radioisotope iodine (-131). MW: 145.5 kD. |
|
|
A2815 |
Dalotuzumab (Anti-IGF1R / CD221)
|
Dalotuzumab (Anti-IGF1R / CD221) is a recombinant humanized monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. MW : 146.78 KD. |
|
|
A2373 |
Neihulizumab (Anti-PSGL1 / CD162)
|
Neihulizumab (Anti-PSGL1 / CD162) is a humanized, agonistic monoclonal antibody against P selectin glycoprotein ligand-1 (PSGL-1, SELPLG, CD162) with potential immunosuppressive activity. It can halt the progression of T-cell-mediated autoimmune diseases and acute graft-versus-host disease (GvHD). MW: 150 kD. |
|
|
A2816 |
Visilizumab (Anti-CD3)
|
Visilizumab (Anti-CD3) is a humanized, non-Fc receptor (FcR)-binding IgG2 monoclonal antibody (MoAb) directed against CD3 with potential immunosuppressive activity. Visilizumab has the potential to be used for ulcerative colitis and Crohn's disease research. MW : 144.62 KD. |
|
|
A2817 |
Anti-CD34
|
Anti-CD34 is a humanized monoclonal antibody against CD34 surface antigen on human stem cells. MW: 145.9 KD. |
|
|
A2818 |
Felzartamab (Anti-CD38)
|
Felzartamab (Anti-CD38) is a fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. MW : 143.66 KD. |
|
|
A2819 |
Mezagitamab (Anti-CD38)
|
Mezagitamab (Anti-CD38) is a human, non-agonistic immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) with potential immunomodulating and antineoplastic activities. MW : 144.44 KD. |
|
|
A2820 |
Tregalizumab (Anti-CD4)
|
Tregalizumab (Anti-CD4) is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs). Tregalizumab can be used in the research of autoimmune diseases. MW : 147.42 KD. |
|
|
A2821 |
Anti-CD4 (TRX1)
|
Anti-CD4 (TRX1) is a non-depleting monoclonal IgG1 antibody against CD4. MW : 145.98 KD. |
|
|
A2823 |
Divozilimab (Anti-CD20)
|
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20) with the potential to be used in multiple sclerosis research. MW : 145.26 KD. |
|
|
A2824 |
Letaplimab (Anti-CD47)
|
Letaplimab (Anti-CD47) is a human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47 with potential immunostimulating and antineoplastic activities. MW : 142.88 KD. |
|
|
A2825 |
Ligufalimab (Anti-CD47)
|
Ligufalimab (Anti-CD47) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.58 KD. |
|
|
A2827 |
Urabrelimab (Anti-CD47)
|
Urabrelimab (Anti-CD47) is a human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. MW : 145.46 KD. |
|
|
A2830 |
Gatralimab (Anti-CD52)
|
Gatralimab (Anti-CD52) is an IgG1 anti-CD52 monoclonal antibody with the potential to treat Symptomatic Osteoarthritis. MW : 145.0 KD. |
|
|
A2388 |
Mupadolimab (Anti-NT5E / CD73)
|
Mupadolimab (Anti-NT5E / CD73) is a type II humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. MW: 145.5 kD. |
|
|
A2831 |
Anti-CD59
|
Anti-CD59 is a humanized monoclonal antibody against CD59 with the potential to treat anti-tumour activity. MW: 145.08 KD. |
|
|
A2390 |
Tesnatilimab (Anti-NKG2D / CD314)
|
Tesnatilimab (Anti-NKG2D / CD314) is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody against the immune activating receptor natural-killer group 2, member D receptor protein (NKG2D or KLRK1), with potential immunomodulating and anti-inflammatory activities. MW: 146.5 kD. |
|
|
A2143New |
Anti-mouse 4-1BB (CD137)-InVivo
|
Anti-mouse 4-1BB (CD137)-InVivo reacts with mouse 4-1BB, a TNF receptor superfamily member also known as CD137. |
|
|
A2834 |
Grisnilimab (Anti-CD7)
|
Grisnilimab (Anti-CD7) is an IgG2a monoclonal antibody against CD7. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA. MW : 144.72 KD. |
|
|
A2393 |
Lorvotuzumab (Anti-NCAM1 / CD56)
|
Lorvotuzumab (Anti-NCAM1 / CD56) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine. MW: 145.5 kD. |
|
|
A2836 |
Iladatuzumab (Anti-CD79b)
|
Iladatuzumab (Anti-CD79b) is a humanized IgG1 monoclonal antibody against CD79 B, a cell-surface antigen expressed on mature B cells. MW : 145.18 KD. |
|
|
A2147New |
Anti-mouse CXCR3 (CD183)-InVivo
|
Anti-mouse CXCR3 (CD183)-InVivo reacts with mouse CXCR3 also known as CD183, a 38 kDa chemokine receptor for CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (ITAC). |
|
|
A2395 |
Imaprelimab (Anti-MUC18 / MCAM / CD146)
|
Imaprelimab (Anti-MUC18 / MCAM / CD146) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody with antineoplastic activity. MW: 145.5 kD. |
|
|
A2838 |
Anti-CD9
|
Anti-CD9 is a humanized monoclonal antibody against CD9 with potential anti-tumor activity. MW: 145.98 KD. |
|
|
A2839 |
Anti-CDH1 / E-cadherin / CD324
|
Anti-CDH1 / E-cadherin / CD324 is an IgG1 monoclonal antibody against E-cadherin, an epithelial adhesion molecule. MW: 146.6 KD. |
|
|
A2149New |
Anti-mouse CD19-InVivo
|
Anti-mouse CD19-InVivo reacts with mouse CD19, a B cell-specific 95 kDa transmembrane glycoprotein of the immunoglobulin superfamily. |
|
|
S3301 |
Cynarin
|
Cynarin (Cynarine) is an artichoke phytochemical that possesses a variety of pharmacological features including free-radical scavenging, antioxidant, antihistamic and antiviral activities. Cynarin blocks the interaction between the CD28 of T-cell receptor and CD80 of antigen presenting cells. Cynarin triggers Nrf2 nuclear translocation, restores the balance of glutathione (GSH) and reactive oxygen species (ROS), and inhibits mitochondrial depolarization. |
|
|
A2151New |
Anti-mouse IL-10R (CD210)-InVivo
|
Anti-mouse IL-10R (CD210)-InVivo reacts with mouse IL-10R (IL-10 receptor) also known as CD210. The IL-10R is a class II cytokine receptor and is expressed by a variety of cell types including thymocytes, T lymphocytes, B lymphocytes, NK cells, monocytes, and macrophages. |
|
|
S0525 |
ADH-503 (GB1275)
|
ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b. |
|
|
A2402 |
Anti-Melanotransferrin / CD228
|
Anti-Melanotransferrin / CD228 is an antibody against the melanotransferrin with potential antineoplastic activity.MW: 145.5 kD. |
|
|
A2154New |
Anti-mouse CD86 (B7-2)-InVivo
|
Anti-mouse CD86 (B7-2)-InVivo reacts with mouse CD86 also known as B7-2. CD86 is an 80 kDa Ig superfamily member. |
|
|
A2846 |
Anti-TNFRSF5 / CD40 (Emory U. anti-CD40)
|
Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) is a monoclonal antibody against CD40 (also called TNFRSF5) with potential antitumor activity. MW: 143.74 KD. |
|
|
A2852 |
Anti-CSF1R / M-CSFR / CD115 (LY3022855)
|
Anti-CSF1R / M-CSFR / CD115 (LY3022855) is a recombinant, immunoglobulin, human monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. MW : 179.2 KD. |
|
|
A2411 |
Polzastobart (Anti-LILRB2 / ILT4 / CD85d)
|
Polzastobart (Anti-LILRB2 / ILT4 / CD85d) is a humanized monoclonal antibody directed against the inhibitory immune checkpoint receptor leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2; immunoglobulin-like transcript 4; ILT4; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. |
|
|
A2413 |
Mibavademab (Anti-LEPR / CD295)
|
Mibavademab (Anti-LEPR / CD295) is a humanized monoclonal antibody against LEPR (Leptin receptor). MW: 145.5 kD. |
|
|
A2414 |
Anti-LAMP1 / CD107a
|
Anti-LAMP1 / CD107 is a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) with potential antineoplastic activity. MW: 145.5 kD. |
|
|
A2159New |
Anti-mouse CSF1R (CD115)-InVivo
|
Anti-mouse CSF1R (CD115)-InVivo reacts with mouse colony stimulating factor 1 receptor (CSF1R), also known as macrophage colony-stimulating factor receptor (M-CSFR), and CD115. CSF1R is a single-pass type I membrane protein and member of the platelet-derived growth factor receptor family. |
|
|
A2127 |
Anti-human CD28-InVivo
|
Anti-human CD28-InVivo (Clone: 9.3) monoclonal antibody reacts with human CD28, a 45 kDa costimulatory receptor and a member of the Ig superfamily. It stimulate the proliferation of human T cells in vitro. |
|
|
A2604 |
Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262)
|
Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). It induces cell apoptosis of cancer cells and inhibits tumor growth and can be used for the research of cancer. MW :150 KD. |
|
|
A2130 |
Anti-mouse LFA-1α (CD11a)-InVivo
|
Anti-mouse LFA-1α (CD11a)-InVivo(clone M17/4) is a monoclonal antibody reacts with mouse LFA-1α (lymphocyte function-associated antigen 1 alpha) also known as integrin alpha L chain and CD11a. It plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAM-1 (CD54), ICAM-2 (CD102), and ICAM-3 (CD50), and also functions in lymphocyte costimulatory signaling. |
|
|
A2021 |
Tremelimumab (anti-CTLA-4)
|
Tremelimumab (Ticilimumab, CP-675,206) is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes. |
|
|
A2418 |
Lacutamab (Anti-KIR3DL2 / CD158k)
|
Lacutamab (Anti-KIR3DL2 / CD158k) is a humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. MW: 150 kD. |
|
|
A2023 |
Obinutuzumab (anti-CD20)
|
Obinutuzumab (anti-CD20) (Gazyva, GA101, Gazyvaro, Afutuzumab) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukemia and lymphoma of B-cell origin. MW : 146.1 kD. |
|
|
A2133 |
Anti-mouse LAG-3-InVivo
|
Anti-mouse LAG-3-InVivo (Clone: C9B7W) monoclonal antibody reacts with mouse LAG-3 also known as CD223. LAG-3 promotes immune responses by activating antigen-presenting cells. The C9B7W antibody has been reported to block the function of murine LAG-3 in vivo and in vitro. |
|
|
A2421 |
Efalizumab (Anti-Integrin aL / ITGAL / CD11a)
|
Efalizumab (Anti-Integrin aL / ITGAL / CD11a) is a humanized IgG1 monoclonal antibody directed against CD11a, the alpha subunit of human leukocyte-function-associated antigen type 1 (LFA-1), with immunosuppressant activity. MW: 145.5 kD. |
|
|
A2611 |
Oleclumab (Anti-NT5E / CD73)
|
Oleclumab (Anti-NT5E / CD73) is a human IgG1λ monoclonal antibody targeting the CD73 function. It has an anti-tumor activity and can be used in treatment of advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), mutant non-small-cell lung cancer (NSCLC). MW :143.14 KD. |
|
|
A2871 |
Foralumab (Anti-CD3e)
|
Foralumab (Anti-CD3e) is a monoclonal antibody directed against cluster of differentiation 3 (CD3) epsilon with immunomodulatory activity. MW: 145.56 KD. |
|
|
A2618 |
Anti-Siglec-15 / CD33L3 (NC318)
|
Anti-Siglec-15 / CD33L3 (NC318) is a monoclonal antibody targeting Siglec-15. It can be used as a novel immune suppressor and a potential target for normalization cancer immunotherapy. MW :146.98 KD. |
|
|
A2620 |
Utomilumab (Anti-TNFRSF9 / 4-1BB / CD137)
|
Utomilumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human IgG2 monoclonal antibody targeting the T-cell costimulatory receptor 4-1BB/CD137. It can be used for the research of relapsed/refractory follicular lymphoma (FL), non-Hodgkin lymphomas (NHL). MW :142.78. |
|
|
A2161New |
Anti-mouse ICOSL (CD275)-InVivo
|
Anti-mouse ICOSL (CD275)-InVivo reacts with mouse ICOSL (inducible T cell co-stimulator ligand) also known as CD275, B7RP-1, and B7-H2. ICOSL is a 40 kDa immune checkpoint protein belonging to the Ig receptor superfamily. |
|
|
A2625 |
Anti-TNFSF13 / APRIL / CD256 (BION-1301)
|
Anti-TNFSF13 / APRIL / CD256 (BION-1301) is a humanized antibody targeting a proliferation Inducing Ligand (APRIL, TNFSF13). It can be used in the treatment of IgA nephropathy. MW :150 KD. |
|
|
A2626 |
Enoblituzumab (Anti-B7-H3 / CD276)
|
Enoblituzumab (Anti-B7-H3 / CD276) is a humanized IgG1κ monoclonal antibody targeting human B7-H3 protein. It can be used in the treatment of medullary thyroid cancer (MTC). MW :150 KD. |
|
|
A2884 |
Giloralimab (Anti-TNFRSF5 / CD40)
|
Giloralimab (Anti-TNFRSF5 / CD40) is an agonistic monoclonal antibody directed against the B-cell surface antigen CD40 with potential antineoplastic activity. MW: 145.26 KD. |
|
|
S8908 |
AB680
|
AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73. |
|
|
A2632 |
Samalizumab (Anti-CD200)
|
Samalizumab (Anti-CD200) is a humanized monoclonal antibody that specifically targets CD200. It can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research. MW :144.84 KD. |
|
|
A2634 |
Bleselumab (Anti-TNFRSF5 / CD40)
|
Bleselumab (Anti-TNFRSF5 / CD40) is a human monoclonal antibody (mAb) targeting human CD40. It has the potential to prevents organ transplant rejection. MW :150 KD. |
|
|
A2635 |
Sotigalimab (Anti-TNFRSF5 / CD40)
|
Sotigalimab (Anti-TNFRSF5 / CD40) is an agonistic monoclonal antibody targeting CD40. It can be used for the research of metastatic pancreatic adenocarcinoma.MW :144.54 KD. |
|
|
A2636 |
Dacetuzumab (Anti-TNFRSF5 / CD40)
|
Dacetuzumab (Anti-TNFRSF5 / CD40) is a humanized IgG1, monoclonal antibody targeting CD40. Ithas anti-lymphoma activity and can be used for multiple myeloma research. MW :150 KD. |
|
|
A2166New |
Anti-mouse CD28(37.51)-InVivo
|
Anti-mouse CD28(37.51)-InVivo reacts with mouse CD28, a 45 kDa costimulatory receptor and a member of the Ig superfamily. CD28 is expressed by thymocytes, most peripheral T cells, and NK cells. |
|
|
A2039 |
Isatuximab (anti-CD38)
|
Isatuximab (anti-CD38) (SAR650984, hu38SB19) is an IgG1-derived monoclonal antibody that binds to a specific extracellular epitope of CD38 receptor with a kd of 0.12 nM. |
|
|
A2648 |
Anti-DC-SIGN / CD209
|
Anti-DC-SIGN / CD209 is a humanized monoclonal antibody that specifically targets DC-SIGN. It inhibits infection caused by human cytomegalovirus (CMV) in immunocompromised patients, namely in organ-transplanted recipients or AIDS patients. ME :146.62 KD. |
|
|
A2904 |
Anti-CD19 (Immunomedics hA19)
|
Anti-CD19 (Immunomedics hA19) is a humanized IgG1kappa monoclonal antibody targated against CD19 with the potential to treat autoimmune diseases. MW: 147.32 KD. |
|
|
A2650 |
Anti-TNFRSF21 / DR6 / CD358
|
Anti-TNFRSF21 / DR6 / CD358 is a humanized monoclonal antibody that specifically targets TNFRSF21. It can be used in treatment of cancer. MW :150 KD. |
|
|
A2906 |
Anti- FcRL5 / IRTA2 / CD307e (DFRF4539A)
|
Anti- FcRL5 / IRTA2 / CD307e (DFRF4539A) is a monoclonal antibody directed against Fc receptor homolog 5 (FcRH5, IFGP5, BXMAS1, CD307, IRTA2) with potential antineoplastic activity. MW: 144.68 KD. |
|
|
A2914 |
Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134)
|
Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4) with potential immunostimulatory activity. MW: 144.18 KD. |
|
|
A2921 |
Lemzoparlimab (Anti-CD47)
|
Lemzoparlimab (anti-CD47) is a human monoclonal antibody targeting the human cell surface antigen CD47 with potential phagocytosis-inducing and antineoplastic activities. MW: 145.58 KD. |
|
|
A2922 |
Lilotomab (Anti-TSPAN26 / CD37)
|
Lilotomab (Anti-TSPAN26 / CD37) is a murine immunoglobulin G1 (IgG1) monoclonal antibody directed against the CD37 antigen with potential antineoplastic activity. MW: 145.64 KD. |
|
|
E1276 |
MK-0159
|
MK-015(Compound 37) is an inhibitor of CD38. MK-0159 inhibits human, mouse, and rat CD38 (cell-free assays) with IC50 values of 22, 3, and 70 nM, respectively. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart. |
|
|
A2935 |
Mirzotamab (Anti-B7-H3 / CD276)
|
Mirzotamab (Anti-B7-H3 / CD276) is a human IgG1κ monoclonal antibody targeting CD276/B7-H3. Mirzotamab is used to produce Mirzotamab clezutoclax antibody drug conjugate (ADC). MW: 144.86 KD. |
|
|
A2937 |
Anti-ICOS / CD278 (MEDI-570)
|
Anti-ICOS/CD278 (MEDI-570) is a Fc-optimized humanized immunoglobulin (Ig) G1 monoclonal antibody (MoAb) directed against the inducible T-cell co-stimulator (ICOS, CD278) with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat non-Hodgkin lymphomas. MW: 146.82 KD. |
|
|
A2683 |
Tavolixizumab (Anti-TNFRSF4 / OX40 / CD134)
|
Tavolixizumab (Anti-TNFRSF4 / OX40 / CD134) is a human monoclonal antibody targeting TNFRSF4 (TNF receptor superfamily member 4) and OX40. It can be used in cancer immunology research. MW :146.36 KD. |
|
|
A2501 |
Lumiliximab (Anti-FceR2 / CD23)
|
Lumiliximab (Anti-FceR2 / CD23) is a monoclonal antibody targeting CD23, that inhibits allergen-induced responses. MW: 145.5 KD. |
|
|
A2691 |
Anti-SIRPa / CD172a
|
Anti-SIRPa / CD172a is an immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. MW : 147.06 kD. |
|
|
A2697 |
Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266)
|
Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD. |
|
|
A2512 |
Adecatumumab (Anti-EpCAM / TROP1 / CD326)
|
Adecatumumab (Anti-EpCAM / TROP1 / CD326) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status. MW: 145.5 KD. |
|
|
A2513 |
Anti-ENTPD1 / CD39
|
Anti-ENTPD1 / CD39 (TTX-030) is a fully human monoclonal antibody directed targeting the cell surface receptor CD39. It specifically binds to the CD39 antigen and inhibits both the conversion of adenosine triphosphate (ATP) to adenosine monophosphate (AMP) and the subsequent generation of immunosuppressive extracellular adenosine in the tumor microenvironment (TME). MW: 145.5 KD. |
|
|
A2514 |
Carotuximab (Anti-Endoglin / CD105)
|
Carotuximab (Anti-Endoglin / CD105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions. MW: 145.5 KD. |
|
|
S7487 |
YYA-021
|
YYA-021 is a CD4-mimic HIV entry inhibitor, competitively inhibiting the interaction between gp120 and CD4. |
|
|
A2707 |
Anti-MPL / TPOR / CD110 (TA136)
|
Anti-MPL / TPOR / CD110 (TA136) is antibody binds to MPL and recognizes a tertial structure of MPL. It can be potentially used in the treatment of congenital amegakaryocytic thrombocytopenia. MW: 143.58 KD. |
|
|
E1305 |
RBN013209
|
RBN013209 is a potent inhibitor of CD38 with an IC50 of 0.01-0.1 μM for human CD38. It can be used for the research of cancer. |
|
|
A2969 |
Ocaratuzumab (Anti-CD20)
|
Ocaratuzumab (anti-CD20) is a Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC). MW: 145.38 kD. |
|
|
A2971 |
Ofatumumab (Anti-CD20)
|
Ofatumumab (Anti-CD20) is a fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. MW: 145.94 kD. |
|
|
A2531 |
Anti-CSF2Rb / CD131
|
Anti-CSF2Rb / CD131 (CSL311) is a monoclonal antibody that targets CSF2Rb and CD131. It is used in treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis. MW: 145.5 KD. |
|
|
A2532 |
Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116)
|
Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. MW: 145.5 KD. |
|
|
A2125 |
Anti-mouse OX40 (CD134)-InVivo
|
Anti-mouse OX40 (CD134)-InVivo (Clone: OX-86) monoclonal antibody reacts with mouse OX-40 also known as CD134. OX-40 plays a major role in regulating both CD4 and CD8 T cell clonal expansion. Anti-mouse OX40 (CD134)-InVivo treatment strongly enhances the generation of antigen-specific effector T cells, prevents the induction of T cell tolerance, and delays tumor growth in vivo. |
|
|
A2542 |
Tepoditamab (Anti-CLEC12A / CD371)
|
Tepoditamab (Anti-CLEC12A / CD371) is a bispecific monoclonal antibody that targets and binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research. MW: 145.5 KD. |
|
|
A2986 |
Omburtamab (Anti-B7-H3 / CD276)
|
Omburtamab (Anti-B7-H3 / CD276) is a monoclonal antibody targeting CD276 (also known as B7-H3). It can bind tumor tissues and be used in various cancers research like non-small cell lung cancer (NSCLC). MW :145.04 KD. |
|
|
A2549 |
Anti-CD98
|
Anti-CD98 (KHK2898) is an antibody targeting CD98. MW: 145.5 KD. |
|
|
A2992 |
Oportuzumab (Anti-EpCAM / TROP1 / CD326)
|
Oportuzumab (Anti-EpCAM / TROP1 / CD326) is a humanized monoclonal antibody targeting EpCAM. It exhibits potential in treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. MW :145.4 KD. |
|
|
A2550 |
Polatuzumab (Anti-CD79b)
|
Polatuzumab (Anti-CD79b) is a monoclonal antibody which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. MW: 145.5 KD. |
|
|
A2993 |
Encelimab (Anti-LAG3 / CD223)
|
Encelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody targeting the inhibitory receptor lymphocyte activation gene 3 protein (LAG3). It has potential immune checkpoint inhibitory and antineoplastic, antitumor activity. MW :144.58 KD. |
|
|
A2551 |
Milatuzumab (Anti-CD74)
|
Milatuzumab (Anti-CD74) is a humanized monoclonal antibody targeting CD74, a integral membrane protein. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death. MW:145.5 KD. |
|
|
A2994 |
Favezelimab (Anti-LAG3 / CD223)
|
Favezelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody that targets LAG-3. It has the potential for colorectal cancer (CRC) research. MW :145.98 KD. |
|
|
A2552 |
Itolizumab (Anti-CD6)
|
Itolizumab (Anti-CD6) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis, COVID-19. MW:145.5 KD. |
|
|
A2995 |
Fianlimab (Anti-LAG3 / CD223)
|
Fianlimab (Anti-LAG3 / CD223) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells. It has anti-tumour activity and can be used in treatment of advanced melanoma. MW :145.72 KD. |
|
|
A2034 |
Elotuzumab (anti-SLAMF7)
|
Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity. |
-
Nat Commun, 2024, 15(1):1367
-
J Cancer, 2024, 15(10):3065-3075
-
J Cancer, 2024, 15(10):3065-3075
|
|
A2553 |
Alemtuzumab (Anti-CD52)
|
Alemtuzumab (Anti-CD52) is a humanized monoclonal antibody targeting against CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. MW:145.5 KD. |
|
|
A2996 |
Ieramilimab (Anti-LAG3 / CD223)
|
Ieramilimab (Anti-LAG3 / CD223) is a humanized IgG4 monoclonal antibody that targets LAG-3. It has antitumor activity and can be used in treatment of advanced malignancies MW :146.78 KD. |
|
|
A2554 |
Anti-CD46
|
Anti-CD46 (FOR46) is a human monoclonal antibody targeting against CD46. It specifically targets and binds to a specific conformational epitope on the immune modulatory receptor CD46 expressed on certain tumor cells. MW:145.5 KD. |
|
|
A2997 |
Miptenalimab (Anti-LAG3 / CD223)
|
Miptenalimab (Anti-LAG3 / CD223) is an anti-human LAG-3 antibody. It leads to an increased immune cell responses. MW :146.12 KD. |
|
|
D4005 |
Vorsetuzumab mafodotin
|
Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the extracellular domain of the human CD70 molecule, and a cytotoxic tubulin polymerization inhibitor. It is used in the treatment of renal cell carcinoma. |
|
|
A2556 |
Ibalizumab (Anti-CD4)
|
Ibalizumab (Anti-CD4) is a humanised IgG4 monoclonal antibody, targeting C4. It prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research. MW:145.5 KD. |
|
|
A2559 |
Galiximab (Anti-CD28L / CD80)
|
Galiximab (Anti-CD28L/CD80) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody targeting against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma. MW:145.5 KD. |
|
|
A2560 |
Anti-CD28
|
Anti-CD28 (FR104) is an antibody targeting CD28. MW:145.5 KD. |
|
|
A2747 |
Cusatuzumab (Anti-TNFSF7 / CD27L / CD70)
|
Cusatuzumab (Anti-TNFSF7 / CD27L / CD70) is a defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML). MW: 144.36 kD. |
|
|
A2561 |
Ocrelizumab (Anti-CD20)
|
Ocrelizumab (Anti-CD20) is a recombinant humanized monoclonal IgG1 antibody that selectively targets CD20 antigen present on B-cells. It is used to treat relapsing remitting multiple sclerosis. MW:145.5 KD. |
|
|
A2748 |
Anti-SCFR / c-Kit / CD117 (CDX-0158)
|
Anti-SCFR / c-Kit / CD117 (CDX-0158) is a humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. CDX‐0159 inhibits SCF‐dependent KIT and mast cell activation. MW: 145.1 kD. |
|
|
A2563 |
Tafasitamab (Anti-CD19)
|
Tafasitamab (Anti-CD19) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigen CD19. It is used in combination with allogeneic NK cell therapy in treatment of B-cell non-Hodgkin's lymphoma. MW:145.5 KD. |
|
|
A2750 |
Anti-FcgR3a / CD16a (AFM13)
|
Anti-FcgR3a / CD16a (AFM13) is a tetravalent bispecific antibody directed against human CD30 and the human low affinity IgG Fc region receptor (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. MW: 143.56 kD. |
|
|
A2564 |
Inebilizumab (Anti-CD19)
|
Inebilizumab (Anti-CD19) is an monoclonal antibody targeting CD19 antigen present on B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research. MW:145.5 KD. |
|
|
A2754 |
Anti-TREM1 / CD354 (PY159)
|
Anti-TREM1 / CD354 (PY159) is a humanized agonistic monoclonal antibody targeting triggering receptor expressed on myeloid cells 1 (TREM1), with potential immunomodulating and antineoplastic activities. MW: 143.66 kD. |
|
|
A2312 |
Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70)
|
Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) is a humanized monoclonal antibody that specifically recognizes and binds to CD70 molecular. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells and shows inhibitory efficacy against Burkitt’s lymphoma. MW : 150 kDa. |
|
|
A2313 |
Dapirolizumab (Anti-TNFSF5 / CD40L / CD154)
|
Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) is a humanized immunoglobulin monoclonal antibody that targets TNFSF5. MW : 150 kDa. |
|
|
A2314 |
Oxelumab (Anti-TNFSF4 / OX40L / CD252)
|
Oxelumab (Anti-TNFSF4 / OX40L / CD252) is a human monoclonal antibody against the OX40 ligand (OX40L) with the potential to be used for asthma research. MW : 145.5 kDa. |
|
|
S6347 |
5'-N-Ethylcarboxamidoadenosine (NECA)
|
5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway. |
|
|
A2758 |
Drozitumab (Anti-TNFRSF10B / TRAILR2 / CD262)
|
Drozitumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human monoclonal antibody targeted against the death receptor DR5 (TRAILR2, CD262, TNFRSF10B) with potent anti-tumor activity against rhabdomyosarcoma (RMS) xenografts. MW: 150 kD. |
|
|
A2316 |
Belimumab (Anti-TNFSF13B / BAFF / CD257)
|
Belimumab (Anti-TNFSF13B / BAFF / CD257) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. MW : 144.56 kDa. |
|
|
A2759 |
Selicrelumab (Anti-TNFRSF5 / CD40)
|
Selicrelumab (anti-TNFRSF5 / CD40) is a human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. It induces changes in the tumor microenvironment and can be used for the research of pancreatic cancer and neoadjuvant tudies. MW: 146.2 kD. |
|
|
A2136New |
Anti-mouse CD40-InVivo
|
Anti-mouse CD40-InVivo reacts with mouse CD40 also known as Bp50. CD40 is a type I transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. |
|
|
D4012 |
Polatuzumab vedotin-piiq
|
Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). |
|
|
A2317 |
Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256)
|
Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256) is a fully humanized IgG2κ monoclonal antibody that targets the B-cell growth factor APRIL (TNFSF13), with the potential to treat IgA nephropathy (IgAN). MW : 145.5 KD. |
|
|
A2760 |
Lintuzumab (Anti-Siglec-3 / CD33)
|
Lintuzumab (HuM195) is a humanized monoclonal antibody that targets CD33, a 67-kDa cell surface glycoprotein expressed on most myeloid leukemia cells. MW: 145. 24 kD. |
|
|
A2762 |
Amlitelimab (Anti-TNFSF4 / OX40L / CD252)
|
Amlitelimab (Anti-TNFSF4 / OX40L / CD252) is a nondepleting IgG4 human anti-OX40L monoclonal antibody with the potential to treat atopic dermatitis. MW: 145.94 kD. |
|
|
A2140New |
Anti-mouse/human/rat CD47 (IAP)-InVivo
|
Anti-mouse/human/rat CD47 (IAP)-InVivo reacts with mouse CD47 otherwise known as integrin-associated protein (IAP). CD47 is an approximately 50 kDa glycosylated five transmembrane protein that is ubiquitously expressed by both hematopoietic cells such as T and B lymphocytes, monocytes, platelets and erythrocytes and non-hematopoietic cells. |
|
|
D4016 |
Iladatuzumab vedotin
|
Iladatuzumab vedotin (DCDS0780A;RO7032005 ), is an antibody-drug conjugate (ADC) composed of CD79B (immunoglobulin-associated CD79 beta) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research. |
|
|
D4017 |
Pinatuzumab vedotin
|
Pinatuzumab Vedotin (RG-7593, DCDT2980S, DCDT-2989S), is an antibody-drug conjugate (ADC) composed of CD22 (Sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. |
|
|
A2321 |
Urelumab (Anti-TNFRSF9 / 4-1BB / CD137)
|
Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. MW : 146.5 KD. |
|
|
A2322 |
Brentuximab (Anti-TNFRSF8 / CD30)
|
Brentuximab (Anti-TNFRSF8 / CD30) is a chimeric monoclonal antibody targeting anti-CD30 with antineoplastic activity. It has the potential to alter the disease course of non-MF/SS CTCLs. MW : 145.38 KD. |
|
|
A2323 |
Varlilumab (Anti-TNFRSF7 / CD27)
|
Varlilumab (Anti-TNFRSF7 / CD27) is a human monoclonal antibody with activity against the CD27 receptor. It exhibits potential immunostimulating and antineoplastic activity. MW : 150 KD. |
|
|
A2324 |
Iscalimab (Anti-TNFRSF5 / CD40)
|
Iscalimab (Anti-TNFRSF5 / CD40) is a non-depleting IGg1 monoclonal antibody targeting CD40. Iscalimab can be used for research on Graves' hyperthyroidism and autoimmune diseases. MW : 145.5 KD. |
|
|
A2325 |
Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134)
|
Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134) is a monoclonal antibody targeting TNFRSF4. MW : 145.5 KD. |
|
|
A2768 |
Alomfilimab (Anti-ICOS / CD278)
|
Alomfilimab (Anti-ICOS / CD278) is a human immunoglobulin G1 (IgG1) kappa monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. MW: 146.5 kD. |
|
|
A2326 |
Telazorlimab (Anti-TNFRSF4 / OX40 / CD134)
|
Telazorlimab (Anti-TNFRSF4 / OX40 / CD134) is a humanized monoclonal antibody against the OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for research on autoimmune diseases. MW : 145.5 KD. |
|
|
A2327 |
Ragifilimab (Anti-TNFRSF18 / GITR / CD357)
|
Ragifilimab (Anti-TNFRSF18 / GITR / CD357) is an anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody with potential immune checkpoint modulating activity. MW : 145.5 KD. |
|
|
S6727 |
AX-024 HCl
|
AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A. |
|
|
A2328 |
Belantamab (Anti-TNFRSF17 / BCMA / CD269)
|
Belantamab (Anti-TNFRSF17 / BCMA / CD269) is a humanized monoclonal antibody directed against the B-cell maturation antigen (BCMA) that can be used in the synthesis of an antibody-drug conjugate (ADC), Belantamab mafodotin. MW : 145.5 KD. |
|
|
A2329 |
Ianalumab (Anti-TNFRSF13C / BAFFR / CD268)
|
Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) is a fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. MW : 145.5 KD. |
|
|
D4034 |
Lorvotuzumab mertansine
|
Lorvotuzumab mertansine (IMGN901, LM) is an antibody-drug conjugate, linking an anti-mitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab). |
|
|
A2332 |
Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261)
|
Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. MW : 145.5 KD. |
|
|
A2334 |
Tisotumab (Anti-Tissue factor / CD142)
|
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody that targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. MW : 145.5 KD. |
|
|
A2592 |
Praluzatamab (Anti-ALCAM / CD166)
|
Praluzatamab (Anti-ALCAM / CD166) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). It can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates)which is used for research of cancers. MW : 150 KD. |
|
|
D4039 |
Praluzatamab ravtansine
|
Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. |
|
|
A2338 |
Ontuxizumab (Anti-TEM1 / Endosialin / CD248)
|
Ontuxizumab (Anti-TEM1/endosialin/ CD248) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with potential anti-angiogenic and antineoplastic activities. MW : 145.5 KD |
|
|
A2053 |
Monalizumab (Anti-Human CD159a)
|
Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors. |
|
|
A2342 |
Indatuximab (Anti-Syndecan-1 / CD138)
|
Indatuximab (Anti-Syndecan-1/CD138) is an antibody against Syndecan-1. MW : 145.5 KD |
|
|
D4045 |
Brentuximab vedotin
|
Brentuximab vedotin (SGN-35; Adcetris,cAC10-vcMMAE) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma. |
|
|
A2793 |
Anti-CD151
|
Anti-CD151 is an anti-CD151 monoclonal antibody (mAb) with potential anti-metastatic and anti-tumor activity activity. MW: 146.76 KD. |
|
|
A2794 |
Anti-EMMPRIN / CD147
|
Anti-EMMPRIN / CD147 is a monoclonal antibody against extracellular matrix metalloproteinase inducer (EMMPRIN; CD147) with potential anti-proliferative activity. MW: 145.42 KD. |
|
|
A2795 |
Denintuzumab (Anti-CD19)
|
Denintuzumab (anti-CD19) is a recombinant humanized anti-CD19 monoclonal antibody that can be used in the research of acute lymphoblastic leukemia. Denintuzumab can be used to synthesize ADC antibody Denintuzumab Mafodotin (SGN-CD19A). MW: 145.0 kD. |
|
|
D4051 |
Tisotumab vedotin
|
Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer. |
|
|
A2354 |
Anti-SLAMF6 / CD352
|
Anti-SLAMF6 / CD352 is a humanized monoclonal antibody (EC-mAb) targeting CD352 (SLAM family member 6; SLAM6) with potential antineoplastic activity. MW : 145.5 KD |
|
|
A2357 |
Vadastuximab (Anti-Siglec-3 / CD33)
|
Vadastuximab (Anti-Siglec-3 / CD33) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine. MW : 150 KD. |
|
|
A2358 |
Inotuzumab (Anti-Siglec-2 / CD22)
|
Inotuzumab (Anti-Siglec-2 / CD22) is a humanized IgG4, κ monoclonal antibody that targets CD22. Inotuzumab can be used for the research of acute lymphoblastic leukaemia and non-Hodgkin lymphoma. MW : 144.78 kD. |
|
|
A2361 |
Pepinemab (Anti-SEMA4D / CD100)
|
Pepinemab (Anti-SEMA4D / CD100) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), which is a regulator of neuronal development and plays a role in a variety of cellular processes. MW : 145.5 kD. |
|
|
A2804 |
Coltuximab (Anti-CD19)
|
Coltuximab (Anti-CD19) is humanized IgG1 monoclonal antibody against CD19 with potential antineoplastic activity. MW : 144.7 KD. |
|
|
A2362 |
Anti-SCFR / c-Kit / CD117
|
Anti-SCFR / c-Kit / CD117 is a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) with potential antineoplastic activity. MW : 150 kD. |
|
|
A2805 |
Ripertamab (Anti-CD20)
|
Ripertamab (Anti-CD20) is a chimeric monoclonal antibody directed against human CD20 with potential antineoplastic activity. MW : 144.56 KD. |
|
|
A2806 |
Anti-CD20 (TRU-015)
|
Anti-CD20 (TRU-015) is a small proprietary antibody-based single-chain polypeptide that binds to CD20 and effectively depleted B cells. It exhibits anti-tumor activity in human tumor xenograft models. MW : 145.4 KD. |
|
|
A2807 |
Ublituximab (Anti-CD20)
|
Ublituximab (Anti-CD20) is a chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. MW : 145.22 KD. |
|
|
A2808 |
Veltuzumab (Anti-CD20)
|
Veltuzumab (Anti-CD20) is a humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. MW : 145.22 KD. |
|
|
A2809 |
Zuberitamab (Anti-CD20)
|
Zuberitamab (Anti-CD20) is a human monoclonal antibody that targets CD20, with the potential to be used in research on diffuse large B-cell lymphoma. MW : 145.48 KD. |
|
|
A2368 |
Roledumab (Anti-RHD / CD240d)
|
Roledumab (Anti-RHD / CD240d) is a human recombinant monoclonal anti-RhD antibody with the potential to prevent RhD allo-immunization. MW: 145.5 kD. |
|
|
A2837 |
Anti-CD83
|
Anti-CD83 is a humanized monoclonal antibody against CD83 with the potential to treat auto-immune diseases. MW: 144.8 KD. |
|
|
A2027 |
Daratumumab (anti-CD38)
|
Daratumumab (anti-CD38) is a recombinant monoclonal antibody to CD38. Daratumumab is an investigational anti-cancer drug which is indicated for the treatment of adult patients with multiple myeloma. MW =145.4 kDa. |
- Brain Behav Immun Health, 2024, 42:100865
- J Exp Med, 2022, 219(9)e20220214
|
|
A2029 |
Relatlimab (anti-LAG-3)
|
Relatlimab (BMS-986016, RELA) is a human LAG-3 specific monoclonal antibody that binds to LAG-3 on T cells, restoring effector function of exhausted T cells. |
- Mol Ther Nucleic Acids, 2024, 35(2):102225
- J Clin Invest, 2023, 133(9)e164528
|
|
A2372 |
Apamistamab (Anti-PTPRC / CD45)
|
Apamistamab (Anti-PTPRC / CD45) is an IgG1 anti-CD45 monoclonal antibody (MoAb). Note: This antibody is not labeled with the radioisotope iodine (-131). MW: 145.5 kD. |
|
|
A2815 |
Dalotuzumab (Anti-IGF1R / CD221)
|
Dalotuzumab (Anti-IGF1R / CD221) is a recombinant humanized monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. MW : 146.78 KD. |
|
|
A2373 |
Neihulizumab (Anti-PSGL1 / CD162)
|
Neihulizumab (Anti-PSGL1 / CD162) is a humanized, agonistic monoclonal antibody against P selectin glycoprotein ligand-1 (PSGL-1, SELPLG, CD162) with potential immunosuppressive activity. It can halt the progression of T-cell-mediated autoimmune diseases and acute graft-versus-host disease (GvHD). MW: 150 kD. |
|
|
A2816 |
Visilizumab (Anti-CD3)
|
Visilizumab (Anti-CD3) is a humanized, non-Fc receptor (FcR)-binding IgG2 monoclonal antibody (MoAb) directed against CD3 with potential immunosuppressive activity. Visilizumab has the potential to be used for ulcerative colitis and Crohn's disease research. MW : 144.62 KD. |
|
|
A2817 |
Anti-CD34
|
Anti-CD34 is a humanized monoclonal antibody against CD34 surface antigen on human stem cells. MW: 145.9 KD. |
|
|
A2818 |
Felzartamab (Anti-CD38)
|
Felzartamab (Anti-CD38) is a fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. MW : 143.66 KD. |
|
|
A2819 |
Mezagitamab (Anti-CD38)
|
Mezagitamab (Anti-CD38) is a human, non-agonistic immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) with potential immunomodulating and antineoplastic activities. MW : 144.44 KD. |
|
|
A2820 |
Tregalizumab (Anti-CD4)
|
Tregalizumab (Anti-CD4) is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs). Tregalizumab can be used in the research of autoimmune diseases. MW : 147.42 KD. |
|
|
A2821 |
Anti-CD4 (TRX1)
|
Anti-CD4 (TRX1) is a non-depleting monoclonal IgG1 antibody against CD4. MW : 145.98 KD. |
|
|
A2823 |
Divozilimab (Anti-CD20)
|
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20) with the potential to be used in multiple sclerosis research. MW : 145.26 KD. |
|
|
A2824 |
Letaplimab (Anti-CD47)
|
Letaplimab (Anti-CD47) is a human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47 with potential immunostimulating and antineoplastic activities. MW : 142.88 KD. |
|
|
A2825 |
Ligufalimab (Anti-CD47)
|
Ligufalimab (Anti-CD47) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.58 KD. |
|
|
A2827 |
Urabrelimab (Anti-CD47)
|
Urabrelimab (Anti-CD47) is a human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. MW : 145.46 KD. |
|
|
A2830 |
Gatralimab (Anti-CD52)
|
Gatralimab (Anti-CD52) is an IgG1 anti-CD52 monoclonal antibody with the potential to treat Symptomatic Osteoarthritis. MW : 145.0 KD. |
|
|
A2388 |
Mupadolimab (Anti-NT5E / CD73)
|
Mupadolimab (Anti-NT5E / CD73) is a type II humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. MW: 145.5 kD. |
|
|
A2831 |
Anti-CD59
|
Anti-CD59 is a humanized monoclonal antibody against CD59 with the potential to treat anti-tumour activity. MW: 145.08 KD. |
|
|
A2390 |
Tesnatilimab (Anti-NKG2D / CD314)
|
Tesnatilimab (Anti-NKG2D / CD314) is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody against the immune activating receptor natural-killer group 2, member D receptor protein (NKG2D or KLRK1), with potential immunomodulating and anti-inflammatory activities. MW: 146.5 kD. |
|
|
A2143New |
Anti-mouse 4-1BB (CD137)-InVivo
|
Anti-mouse 4-1BB (CD137)-InVivo reacts with mouse 4-1BB, a TNF receptor superfamily member also known as CD137. |
|
|
A2834 |
Grisnilimab (Anti-CD7)
|
Grisnilimab (Anti-CD7) is an IgG2a monoclonal antibody against CD7. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA. MW : 144.72 KD. |
|
|
A2393 |
Lorvotuzumab (Anti-NCAM1 / CD56)
|
Lorvotuzumab (Anti-NCAM1 / CD56) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine. MW: 145.5 kD. |
|
|
A2836 |
Iladatuzumab (Anti-CD79b)
|
Iladatuzumab (Anti-CD79b) is a humanized IgG1 monoclonal antibody against CD79 B, a cell-surface antigen expressed on mature B cells. MW : 145.18 KD. |
|
|
A2147New |
Anti-mouse CXCR3 (CD183)-InVivo
|
Anti-mouse CXCR3 (CD183)-InVivo reacts with mouse CXCR3 also known as CD183, a 38 kDa chemokine receptor for CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (ITAC). |
|
|
A2395 |
Imaprelimab (Anti-MUC18 / MCAM / CD146)
|
Imaprelimab (Anti-MUC18 / MCAM / CD146) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody with antineoplastic activity. MW: 145.5 kD. |
|
|
A2838 |
Anti-CD9
|
Anti-CD9 is a humanized monoclonal antibody against CD9 with potential anti-tumor activity. MW: 145.98 KD. |
|
|
A2839 |
Anti-CDH1 / E-cadherin / CD324
|
Anti-CDH1 / E-cadherin / CD324 is an IgG1 monoclonal antibody against E-cadherin, an epithelial adhesion molecule. MW: 146.6 KD. |
|
|
A2149New |
Anti-mouse CD19-InVivo
|
Anti-mouse CD19-InVivo reacts with mouse CD19, a B cell-specific 95 kDa transmembrane glycoprotein of the immunoglobulin superfamily. |
|
|
A2151New |
Anti-mouse IL-10R (CD210)-InVivo
|
Anti-mouse IL-10R (CD210)-InVivo reacts with mouse IL-10R (IL-10 receptor) also known as CD210. The IL-10R is a class II cytokine receptor and is expressed by a variety of cell types including thymocytes, T lymphocytes, B lymphocytes, NK cells, monocytes, and macrophages. |
|
|
A2402 |
Anti-Melanotransferrin / CD228
|
Anti-Melanotransferrin / CD228 is an antibody against the melanotransferrin with potential antineoplastic activity.MW: 145.5 kD. |
|
|
A2154New |
Anti-mouse CD86 (B7-2)-InVivo
|
Anti-mouse CD86 (B7-2)-InVivo reacts with mouse CD86 also known as B7-2. CD86 is an 80 kDa Ig superfamily member. |
|
|
A2846 |
Anti-TNFRSF5 / CD40 (Emory U. anti-CD40)
|
Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) is a monoclonal antibody against CD40 (also called TNFRSF5) with potential antitumor activity. MW: 143.74 KD. |
|
|
A2852 |
Anti-CSF1R / M-CSFR / CD115 (LY3022855)
|
Anti-CSF1R / M-CSFR / CD115 (LY3022855) is a recombinant, immunoglobulin, human monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. MW : 179.2 KD. |
|
|
A2411 |
Polzastobart (Anti-LILRB2 / ILT4 / CD85d)
|
Polzastobart (Anti-LILRB2 / ILT4 / CD85d) is a humanized monoclonal antibody directed against the inhibitory immune checkpoint receptor leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2; immunoglobulin-like transcript 4; ILT4; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. |
|
|
A2413 |
Mibavademab (Anti-LEPR / CD295)
|
Mibavademab (Anti-LEPR / CD295) is a humanized monoclonal antibody against LEPR (Leptin receptor). MW: 145.5 kD. |
|
|
A2414 |
Anti-LAMP1 / CD107a
|
Anti-LAMP1 / CD107 is a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) with potential antineoplastic activity. MW: 145.5 kD. |
|
|
A2159New |
Anti-mouse CSF1R (CD115)-InVivo
|
Anti-mouse CSF1R (CD115)-InVivo reacts with mouse colony stimulating factor 1 receptor (CSF1R), also known as macrophage colony-stimulating factor receptor (M-CSFR), and CD115. CSF1R is a single-pass type I membrane protein and member of the platelet-derived growth factor receptor family. |
|
|
A2127 |
Anti-human CD28-InVivo
|
Anti-human CD28-InVivo (Clone: 9.3) monoclonal antibody reacts with human CD28, a 45 kDa costimulatory receptor and a member of the Ig superfamily. It stimulate the proliferation of human T cells in vitro. |
|
|
A2604 |
Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262)
|
Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). It induces cell apoptosis of cancer cells and inhibits tumor growth and can be used for the research of cancer. MW :150 KD. |
|
|
A2130 |
Anti-mouse LFA-1α (CD11a)-InVivo
|
Anti-mouse LFA-1α (CD11a)-InVivo(clone M17/4) is a monoclonal antibody reacts with mouse LFA-1α (lymphocyte function-associated antigen 1 alpha) also known as integrin alpha L chain and CD11a. It plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAM-1 (CD54), ICAM-2 (CD102), and ICAM-3 (CD50), and also functions in lymphocyte costimulatory signaling. |
|
|
A2021 |
Tremelimumab (anti-CTLA-4)
|
Tremelimumab (Ticilimumab, CP-675,206) is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes. |
|
|
A2418 |
Lacutamab (Anti-KIR3DL2 / CD158k)
|
Lacutamab (Anti-KIR3DL2 / CD158k) is a humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. MW: 150 kD. |
|
|
A2023 |
Obinutuzumab (anti-CD20)
|
Obinutuzumab (anti-CD20) (Gazyva, GA101, Gazyvaro, Afutuzumab) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukemia and lymphoma of B-cell origin. MW : 146.1 kD. |
|
|
A2133 |
Anti-mouse LAG-3-InVivo
|
Anti-mouse LAG-3-InVivo (Clone: C9B7W) monoclonal antibody reacts with mouse LAG-3 also known as CD223. LAG-3 promotes immune responses by activating antigen-presenting cells. The C9B7W antibody has been reported to block the function of murine LAG-3 in vivo and in vitro. |
|
|
A2421 |
Efalizumab (Anti-Integrin aL / ITGAL / CD11a)
|
Efalizumab (Anti-Integrin aL / ITGAL / CD11a) is a humanized IgG1 monoclonal antibody directed against CD11a, the alpha subunit of human leukocyte-function-associated antigen type 1 (LFA-1), with immunosuppressant activity. MW: 145.5 kD. |
|
|
A2611 |
Oleclumab (Anti-NT5E / CD73)
|
Oleclumab (Anti-NT5E / CD73) is a human IgG1λ monoclonal antibody targeting the CD73 function. It has an anti-tumor activity and can be used in treatment of advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), mutant non-small-cell lung cancer (NSCLC). MW :143.14 KD. |
|
|
A2871 |
Foralumab (Anti-CD3e)
|
Foralumab (Anti-CD3e) is a monoclonal antibody directed against cluster of differentiation 3 (CD3) epsilon with immunomodulatory activity. MW: 145.56 KD. |
|
|
A2618 |
Anti-Siglec-15 / CD33L3 (NC318)
|
Anti-Siglec-15 / CD33L3 (NC318) is a monoclonal antibody targeting Siglec-15. It can be used as a novel immune suppressor and a potential target for normalization cancer immunotherapy. MW :146.98 KD. |
|
|
A2620 |
Utomilumab (Anti-TNFRSF9 / 4-1BB / CD137)
|
Utomilumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human IgG2 monoclonal antibody targeting the T-cell costimulatory receptor 4-1BB/CD137. It can be used for the research of relapsed/refractory follicular lymphoma (FL), non-Hodgkin lymphomas (NHL). MW :142.78. |
|
|
A2161New |
Anti-mouse ICOSL (CD275)-InVivo
|
Anti-mouse ICOSL (CD275)-InVivo reacts with mouse ICOSL (inducible T cell co-stimulator ligand) also known as CD275, B7RP-1, and B7-H2. ICOSL is a 40 kDa immune checkpoint protein belonging to the Ig receptor superfamily. |
|
|
A2625 |
Anti-TNFSF13 / APRIL / CD256 (BION-1301)
|
Anti-TNFSF13 / APRIL / CD256 (BION-1301) is a humanized antibody targeting a proliferation Inducing Ligand (APRIL, TNFSF13). It can be used in the treatment of IgA nephropathy. MW :150 KD. |
|
|
A2626 |
Enoblituzumab (Anti-B7-H3 / CD276)
|
Enoblituzumab (Anti-B7-H3 / CD276) is a humanized IgG1κ monoclonal antibody targeting human B7-H3 protein. It can be used in the treatment of medullary thyroid cancer (MTC). MW :150 KD. |
|
|
A2884 |
Giloralimab (Anti-TNFRSF5 / CD40)
|
Giloralimab (Anti-TNFRSF5 / CD40) is an agonistic monoclonal antibody directed against the B-cell surface antigen CD40 with potential antineoplastic activity. MW: 145.26 KD. |
|
|
A2632 |
Samalizumab (Anti-CD200)
|
Samalizumab (Anti-CD200) is a humanized monoclonal antibody that specifically targets CD200. It can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research. MW :144.84 KD. |
|
|
A2634 |
Bleselumab (Anti-TNFRSF5 / CD40)
|
Bleselumab (Anti-TNFRSF5 / CD40) is a human monoclonal antibody (mAb) targeting human CD40. It has the potential to prevents organ transplant rejection. MW :150 KD. |
|
|
A2635 |
Sotigalimab (Anti-TNFRSF5 / CD40)
|
Sotigalimab (Anti-TNFRSF5 / CD40) is an agonistic monoclonal antibody targeting CD40. It can be used for the research of metastatic pancreatic adenocarcinoma.MW :144.54 KD. |
|
|
A2636 |
Dacetuzumab (Anti-TNFRSF5 / CD40)
|
Dacetuzumab (Anti-TNFRSF5 / CD40) is a humanized IgG1, monoclonal antibody targeting CD40. Ithas anti-lymphoma activity and can be used for multiple myeloma research. MW :150 KD. |
|
|
A2166New |
Anti-mouse CD28(37.51)-InVivo
|
Anti-mouse CD28(37.51)-InVivo reacts with mouse CD28, a 45 kDa costimulatory receptor and a member of the Ig superfamily. CD28 is expressed by thymocytes, most peripheral T cells, and NK cells. |
|
|
A2039 |
Isatuximab (anti-CD38)
|
Isatuximab (anti-CD38) (SAR650984, hu38SB19) is an IgG1-derived monoclonal antibody that binds to a specific extracellular epitope of CD38 receptor with a kd of 0.12 nM. |
|
|
A2648 |
Anti-DC-SIGN / CD209
|
Anti-DC-SIGN / CD209 is a humanized monoclonal antibody that specifically targets DC-SIGN. It inhibits infection caused by human cytomegalovirus (CMV) in immunocompromised patients, namely in organ-transplanted recipients or AIDS patients. ME :146.62 KD. |
|
|
A2904 |
Anti-CD19 (Immunomedics hA19)
|
Anti-CD19 (Immunomedics hA19) is a humanized IgG1kappa monoclonal antibody targated against CD19 with the potential to treat autoimmune diseases. MW: 147.32 KD. |
|
|
A2650 |
Anti-TNFRSF21 / DR6 / CD358
|
Anti-TNFRSF21 / DR6 / CD358 is a humanized monoclonal antibody that specifically targets TNFRSF21. It can be used in treatment of cancer. MW :150 KD. |
|
|
A2906 |
Anti- FcRL5 / IRTA2 / CD307e (DFRF4539A)
|
Anti- FcRL5 / IRTA2 / CD307e (DFRF4539A) is a monoclonal antibody directed against Fc receptor homolog 5 (FcRH5, IFGP5, BXMAS1, CD307, IRTA2) with potential antineoplastic activity. MW: 144.68 KD. |
|
|
A2914 |
Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134)
|
Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4) with potential immunostimulatory activity. MW: 144.18 KD. |
|
|
A2921 |
Lemzoparlimab (Anti-CD47)
|
Lemzoparlimab (anti-CD47) is a human monoclonal antibody targeting the human cell surface antigen CD47 with potential phagocytosis-inducing and antineoplastic activities. MW: 145.58 KD. |
|
|
A2922 |
Lilotomab (Anti-TSPAN26 / CD37)
|
Lilotomab (Anti-TSPAN26 / CD37) is a murine immunoglobulin G1 (IgG1) monoclonal antibody directed against the CD37 antigen with potential antineoplastic activity. MW: 145.64 KD. |
|
|
A2935 |
Mirzotamab (Anti-B7-H3 / CD276)
|
Mirzotamab (Anti-B7-H3 / CD276) is a human IgG1κ monoclonal antibody targeting CD276/B7-H3. Mirzotamab is used to produce Mirzotamab clezutoclax antibody drug conjugate (ADC). MW: 144.86 KD. |
|
|
A2937 |
Anti-ICOS / CD278 (MEDI-570)
|
Anti-ICOS/CD278 (MEDI-570) is a Fc-optimized humanized immunoglobulin (Ig) G1 monoclonal antibody (MoAb) directed against the inducible T-cell co-stimulator (ICOS, CD278) with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat non-Hodgkin lymphomas. MW: 146.82 KD. |
|
|
A2683 |
Tavolixizumab (Anti-TNFRSF4 / OX40 / CD134)
|
Tavolixizumab (Anti-TNFRSF4 / OX40 / CD134) is a human monoclonal antibody targeting TNFRSF4 (TNF receptor superfamily member 4) and OX40. It can be used in cancer immunology research. MW :146.36 KD. |
|
|
A2501 |
Lumiliximab (Anti-FceR2 / CD23)
|
Lumiliximab (Anti-FceR2 / CD23) is a monoclonal antibody targeting CD23, that inhibits allergen-induced responses. MW: 145.5 KD. |
|
|
A2691 |
Anti-SIRPa / CD172a
|
Anti-SIRPa / CD172a is an immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. MW : 147.06 kD. |
|
|
A2697 |
Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266)
|
Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD. |
|
|
A2512 |
Adecatumumab (Anti-EpCAM / TROP1 / CD326)
|
Adecatumumab (Anti-EpCAM / TROP1 / CD326) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status. MW: 145.5 KD. |
|
|
A2513 |
Anti-ENTPD1 / CD39
|
Anti-ENTPD1 / CD39 (TTX-030) is a fully human monoclonal antibody directed targeting the cell surface receptor CD39. It specifically binds to the CD39 antigen and inhibits both the conversion of adenosine triphosphate (ATP) to adenosine monophosphate (AMP) and the subsequent generation of immunosuppressive extracellular adenosine in the tumor microenvironment (TME). MW: 145.5 KD. |
|
|
A2514 |
Carotuximab (Anti-Endoglin / CD105)
|
Carotuximab (Anti-Endoglin / CD105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions. MW: 145.5 KD. |
|
|
A2707 |
Anti-MPL / TPOR / CD110 (TA136)
|
Anti-MPL / TPOR / CD110 (TA136) is antibody binds to MPL and recognizes a tertial structure of MPL. It can be potentially used in the treatment of congenital amegakaryocytic thrombocytopenia. MW: 143.58 KD. |
|
|
A2969 |
Ocaratuzumab (Anti-CD20)
|
Ocaratuzumab (anti-CD20) is a Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC). MW: 145.38 kD. |
|
|
A2971 |
Ofatumumab (Anti-CD20)
|
Ofatumumab (Anti-CD20) is a fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. MW: 145.94 kD. |
|
|
A2531 |
Anti-CSF2Rb / CD131
|
Anti-CSF2Rb / CD131 (CSL311) is a monoclonal antibody that targets CSF2Rb and CD131. It is used in treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis. MW: 145.5 KD. |
|
|
A2532 |
Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116)
|
Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. MW: 145.5 KD. |
|
|
A2125 |
Anti-mouse OX40 (CD134)-InVivo
|
Anti-mouse OX40 (CD134)-InVivo (Clone: OX-86) monoclonal antibody reacts with mouse OX-40 also known as CD134. OX-40 plays a major role in regulating both CD4 and CD8 T cell clonal expansion. Anti-mouse OX40 (CD134)-InVivo treatment strongly enhances the generation of antigen-specific effector T cells, prevents the induction of T cell tolerance, and delays tumor growth in vivo. |
|
|
A2542 |
Tepoditamab (Anti-CLEC12A / CD371)
|
Tepoditamab (Anti-CLEC12A / CD371) is a bispecific monoclonal antibody that targets and binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research. MW: 145.5 KD. |
|
|
A2986 |
Omburtamab (Anti-B7-H3 / CD276)
|
Omburtamab (Anti-B7-H3 / CD276) is a monoclonal antibody targeting CD276 (also known as B7-H3). It can bind tumor tissues and be used in various cancers research like non-small cell lung cancer (NSCLC). MW :145.04 KD. |
|
|
A2549 |
Anti-CD98
|
Anti-CD98 (KHK2898) is an antibody targeting CD98. MW: 145.5 KD. |
|
|
A2992 |
Oportuzumab (Anti-EpCAM / TROP1 / CD326)
|
Oportuzumab (Anti-EpCAM / TROP1 / CD326) is a humanized monoclonal antibody targeting EpCAM. It exhibits potential in treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. MW :145.4 KD. |
|
|
A2550 |
Polatuzumab (Anti-CD79b)
|
Polatuzumab (Anti-CD79b) is a monoclonal antibody which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. MW: 145.5 KD. |
|
|
A2993 |
Encelimab (Anti-LAG3 / CD223)
|
Encelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody targeting the inhibitory receptor lymphocyte activation gene 3 protein (LAG3). It has potential immune checkpoint inhibitory and antineoplastic, antitumor activity. MW :144.58 KD. |
|
|
A2551 |
Milatuzumab (Anti-CD74)
|
Milatuzumab (Anti-CD74) is a humanized monoclonal antibody targeting CD74, a integral membrane protein. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death. MW:145.5 KD. |
|
|
A2994 |
Favezelimab (Anti-LAG3 / CD223)
|
Favezelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody that targets LAG-3. It has the potential for colorectal cancer (CRC) research. MW :145.98 KD. |
|
|
A2552 |
Itolizumab (Anti-CD6)
|
Itolizumab (Anti-CD6) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis, COVID-19. MW:145.5 KD. |
|
|
A2995 |
Fianlimab (Anti-LAG3 / CD223)
|
Fianlimab (Anti-LAG3 / CD223) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells. It has anti-tumour activity and can be used in treatment of advanced melanoma. MW :145.72 KD. |
|
|
A2034 |
Elotuzumab (anti-SLAMF7)
|
Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity. |
- Nat Commun, 2024, 15(1):1367
- J Cancer, 2024, 15(10):3065-3075
- J Cancer, 2024, 15(10):3065-3075
|
|
A2553 |
Alemtuzumab (Anti-CD52)
|
Alemtuzumab (Anti-CD52) is a humanized monoclonal antibody targeting against CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. MW:145.5 KD. |
|
|
A2996 |
Ieramilimab (Anti-LAG3 / CD223)
|
Ieramilimab (Anti-LAG3 / CD223) is a humanized IgG4 monoclonal antibody that targets LAG-3. It has antitumor activity and can be used in treatment of advanced malignancies MW :146.78 KD. |
|
|
A2554 |
Anti-CD46
|
Anti-CD46 (FOR46) is a human monoclonal antibody targeting against CD46. It specifically targets and binds to a specific conformational epitope on the immune modulatory receptor CD46 expressed on certain tumor cells. MW:145.5 KD. |
|
|
A2997 |
Miptenalimab (Anti-LAG3 / CD223)
|
Miptenalimab (Anti-LAG3 / CD223) is an anti-human LAG-3 antibody. It leads to an increased immune cell responses. MW :146.12 KD. |
|
|
A2556 |
Ibalizumab (Anti-CD4)
|
Ibalizumab (Anti-CD4) is a humanised IgG4 monoclonal antibody, targeting C4. It prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research. MW:145.5 KD. |
|
|
A2559 |
Galiximab (Anti-CD28L / CD80)
|
Galiximab (Anti-CD28L/CD80) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody targeting against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma. MW:145.5 KD. |
|
|
A2560 |
Anti-CD28
|
Anti-CD28 (FR104) is an antibody targeting CD28. MW:145.5 KD. |
|
|
A2747 |
Cusatuzumab (Anti-TNFSF7 / CD27L / CD70)
|
Cusatuzumab (Anti-TNFSF7 / CD27L / CD70) is a defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML). MW: 144.36 kD. |
|
|
A2561 |
Ocrelizumab (Anti-CD20)
|
Ocrelizumab (Anti-CD20) is a recombinant humanized monoclonal IgG1 antibody that selectively targets CD20 antigen present on B-cells. It is used to treat relapsing remitting multiple sclerosis. MW:145.5 KD. |
|
|
A2748 |
Anti-SCFR / c-Kit / CD117 (CDX-0158)
|
Anti-SCFR / c-Kit / CD117 (CDX-0158) is a humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. CDX‐0159 inhibits SCF‐dependent KIT and mast cell activation. MW: 145.1 kD. |
|
|
A2563 |
Tafasitamab (Anti-CD19)
|
Tafasitamab (Anti-CD19) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigen CD19. It is used in combination with allogeneic NK cell therapy in treatment of B-cell non-Hodgkin's lymphoma. MW:145.5 KD. |
|
|
A2750 |
Anti-FcgR3a / CD16a (AFM13)
|
Anti-FcgR3a / CD16a (AFM13) is a tetravalent bispecific antibody directed against human CD30 and the human low affinity IgG Fc region receptor (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. MW: 143.56 kD. |
|
|
A2564 |
Inebilizumab (Anti-CD19)
|
Inebilizumab (Anti-CD19) is an monoclonal antibody targeting CD19 antigen present on B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research. MW:145.5 KD. |
|
|
A2754 |
Anti-TREM1 / CD354 (PY159)
|
Anti-TREM1 / CD354 (PY159) is a humanized agonistic monoclonal antibody targeting triggering receptor expressed on myeloid cells 1 (TREM1), with potential immunomodulating and antineoplastic activities. MW: 143.66 kD. |
|
|
A2312 |
Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70)
|
Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) is a humanized monoclonal antibody that specifically recognizes and binds to CD70 molecular. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells and shows inhibitory efficacy against Burkitt’s lymphoma. MW : 150 kDa. |
|
|
A2313 |
Dapirolizumab (Anti-TNFSF5 / CD40L / CD154)
|
Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) is a humanized immunoglobulin monoclonal antibody that targets TNFSF5. MW : 150 kDa. |
|
|
A2314 |
Oxelumab (Anti-TNFSF4 / OX40L / CD252)
|
Oxelumab (Anti-TNFSF4 / OX40L / CD252) is a human monoclonal antibody against the OX40 ligand (OX40L) with the potential to be used for asthma research. MW : 145.5 kDa. |
|
|
A2758 |
Drozitumab (Anti-TNFRSF10B / TRAILR2 / CD262)
|
Drozitumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human monoclonal antibody targeted against the death receptor DR5 (TRAILR2, CD262, TNFRSF10B) with potent anti-tumor activity against rhabdomyosarcoma (RMS) xenografts. MW: 150 kD. |
|
|
A2316 |
Belimumab (Anti-TNFSF13B / BAFF / CD257)
|
Belimumab (Anti-TNFSF13B / BAFF / CD257) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. MW : 144.56 kDa. |
|
|
A2759 |
Selicrelumab (Anti-TNFRSF5 / CD40)
|
Selicrelumab (anti-TNFRSF5 / CD40) is a human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. It induces changes in the tumor microenvironment and can be used for the research of pancreatic cancer and neoadjuvant tudies. MW: 146.2 kD. |
|
|
A2136New |
Anti-mouse CD40-InVivo
|
Anti-mouse CD40-InVivo reacts with mouse CD40 also known as Bp50. CD40 is a type I transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. |
|
|
A2317 |
Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256)
|
Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256) is a fully humanized IgG2κ monoclonal antibody that targets the B-cell growth factor APRIL (TNFSF13), with the potential to treat IgA nephropathy (IgAN). MW : 145.5 KD. |
|
|
A2760 |
Lintuzumab (Anti-Siglec-3 / CD33)
|
Lintuzumab (HuM195) is a humanized monoclonal antibody that targets CD33, a 67-kDa cell surface glycoprotein expressed on most myeloid leukemia cells. MW: 145. 24 kD. |
|
|
A2762 |
Amlitelimab (Anti-TNFSF4 / OX40L / CD252)
|
Amlitelimab (Anti-TNFSF4 / OX40L / CD252) is a nondepleting IgG4 human anti-OX40L monoclonal antibody with the potential to treat atopic dermatitis. MW: 145.94 kD. |
|
|
A2140New |
Anti-mouse/human/rat CD47 (IAP)-InVivo
|
Anti-mouse/human/rat CD47 (IAP)-InVivo reacts with mouse CD47 otherwise known as integrin-associated protein (IAP). CD47 is an approximately 50 kDa glycosylated five transmembrane protein that is ubiquitously expressed by both hematopoietic cells such as T and B lymphocytes, monocytes, platelets and erythrocytes and non-hematopoietic cells. |
|
|
A2321 |
Urelumab (Anti-TNFRSF9 / 4-1BB / CD137)
|
Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. MW : 146.5 KD. |
|
|
A2322 |
Brentuximab (Anti-TNFRSF8 / CD30)
|
Brentuximab (Anti-TNFRSF8 / CD30) is a chimeric monoclonal antibody targeting anti-CD30 with antineoplastic activity. It has the potential to alter the disease course of non-MF/SS CTCLs. MW : 145.38 KD. |
|
|
A2323 |
Varlilumab (Anti-TNFRSF7 / CD27)
|
Varlilumab (Anti-TNFRSF7 / CD27) is a human monoclonal antibody with activity against the CD27 receptor. It exhibits potential immunostimulating and antineoplastic activity. MW : 150 KD. |
|
|
A2324 |
Iscalimab (Anti-TNFRSF5 / CD40)
|
Iscalimab (Anti-TNFRSF5 / CD40) is a non-depleting IGg1 monoclonal antibody targeting CD40. Iscalimab can be used for research on Graves' hyperthyroidism and autoimmune diseases. MW : 145.5 KD. |
|
|
A2325 |
Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134)
|
Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134) is a monoclonal antibody targeting TNFRSF4. MW : 145.5 KD. |
|
|
A2768 |
Alomfilimab (Anti-ICOS / CD278)
|
Alomfilimab (Anti-ICOS / CD278) is a human immunoglobulin G1 (IgG1) kappa monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. MW: 146.5 kD. |
|
|
A2326 |
Telazorlimab (Anti-TNFRSF4 / OX40 / CD134)
|
Telazorlimab (Anti-TNFRSF4 / OX40 / CD134) is a humanized monoclonal antibody against the OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for research on autoimmune diseases. MW : 145.5 KD. |
|
|
A2327 |
Ragifilimab (Anti-TNFRSF18 / GITR / CD357)
|
Ragifilimab (Anti-TNFRSF18 / GITR / CD357) is an anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody with potential immune checkpoint modulating activity. MW : 145.5 KD. |
|
|
A2328 |
Belantamab (Anti-TNFRSF17 / BCMA / CD269)
|
Belantamab (Anti-TNFRSF17 / BCMA / CD269) is a humanized monoclonal antibody directed against the B-cell maturation antigen (BCMA) that can be used in the synthesis of an antibody-drug conjugate (ADC), Belantamab mafodotin. MW : 145.5 KD. |
|
|
A2329 |
Ianalumab (Anti-TNFRSF13C / BAFFR / CD268)
|
Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) is a fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. MW : 145.5 KD. |
|
|
A2332 |
Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261)
|
Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. MW : 145.5 KD. |
|
|
A2334 |
Tisotumab (Anti-Tissue factor / CD142)
|
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody that targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. MW : 145.5 KD. |
|
|
A2592 |
Praluzatamab (Anti-ALCAM / CD166)
|
Praluzatamab (Anti-ALCAM / CD166) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). It can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates)which is used for research of cancers. MW : 150 KD. |
|
|
A2338 |
Ontuxizumab (Anti-TEM1 / Endosialin / CD248)
|
Ontuxizumab (Anti-TEM1/endosialin/ CD248) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with potential anti-angiogenic and antineoplastic activities. MW : 145.5 KD |
|
|
A2053 |
Monalizumab (Anti-Human CD159a)
|
Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors. |
|
|
A2342 |
Indatuximab (Anti-Syndecan-1 / CD138)
|
Indatuximab (Anti-Syndecan-1/CD138) is an antibody against Syndecan-1. MW : 145.5 KD |
|
|
A2793 |
Anti-CD151
|
Anti-CD151 is an anti-CD151 monoclonal antibody (mAb) with potential anti-metastatic and anti-tumor activity activity. MW: 146.76 KD. |
|
|
A2794 |
Anti-EMMPRIN / CD147
|
Anti-EMMPRIN / CD147 is a monoclonal antibody against extracellular matrix metalloproteinase inducer (EMMPRIN; CD147) with potential anti-proliferative activity. MW: 145.42 KD. |
|
|
A2795 |
Denintuzumab (Anti-CD19)
|
Denintuzumab (anti-CD19) is a recombinant humanized anti-CD19 monoclonal antibody that can be used in the research of acute lymphoblastic leukemia. Denintuzumab can be used to synthesize ADC antibody Denintuzumab Mafodotin (SGN-CD19A). MW: 145.0 kD. |
|
|
A2354 |
Anti-SLAMF6 / CD352
|
Anti-SLAMF6 / CD352 is a humanized monoclonal antibody (EC-mAb) targeting CD352 (SLAM family member 6; SLAM6) with potential antineoplastic activity. MW : 145.5 KD |
|
|
A2357 |
Vadastuximab (Anti-Siglec-3 / CD33)
|
Vadastuximab (Anti-Siglec-3 / CD33) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine. MW : 150 KD. |
|
|
A2358 |
Inotuzumab (Anti-Siglec-2 / CD22)
|
Inotuzumab (Anti-Siglec-2 / CD22) is a humanized IgG4, κ monoclonal antibody that targets CD22. Inotuzumab can be used for the research of acute lymphoblastic leukaemia and non-Hodgkin lymphoma. MW : 144.78 kD. |
|
|
A2361 |
Pepinemab (Anti-SEMA4D / CD100)
|
Pepinemab (Anti-SEMA4D / CD100) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), which is a regulator of neuronal development and plays a role in a variety of cellular processes. MW : 145.5 kD. |
|
|
A2804 |
Coltuximab (Anti-CD19)
|
Coltuximab (Anti-CD19) is humanized IgG1 monoclonal antibody against CD19 with potential antineoplastic activity. MW : 144.7 KD. |
|
|
A2362 |
Anti-SCFR / c-Kit / CD117
|
Anti-SCFR / c-Kit / CD117 is a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) with potential antineoplastic activity. MW : 150 kD. |
|
|
A2805 |
Ripertamab (Anti-CD20)
|
Ripertamab (Anti-CD20) is a chimeric monoclonal antibody directed against human CD20 with potential antineoplastic activity. MW : 144.56 KD. |
|
|
A2806 |
Anti-CD20 (TRU-015)
|
Anti-CD20 (TRU-015) is a small proprietary antibody-based single-chain polypeptide that binds to CD20 and effectively depleted B cells. It exhibits anti-tumor activity in human tumor xenograft models. MW : 145.4 KD. |
|
|
A2807 |
Ublituximab (Anti-CD20)
|
Ublituximab (Anti-CD20) is a chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. MW : 145.22 KD. |
|
|
A2808 |
Veltuzumab (Anti-CD20)
|
Veltuzumab (Anti-CD20) is a humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. MW : 145.22 KD. |
|
|
A2809 |
Zuberitamab (Anti-CD20)
|
Zuberitamab (Anti-CD20) is a human monoclonal antibody that targets CD20, with the potential to be used in research on diffuse large B-cell lymphoma. MW : 145.48 KD. |
|
|
A2368 |
Roledumab (Anti-RHD / CD240d)
|
Roledumab (Anti-RHD / CD240d) is a human recombinant monoclonal anti-RhD antibody with the potential to prevent RhD allo-immunization. MW: 145.5 kD. |
|
|